The role of biobehavioral factors and anti-inflammatory medications on the ovarian tumor immune response
Project Number7R01CA276224-02
Former Number1R01CA276224-01A1
Contact PI/Project LeaderTWOROGER, SHELLEY S Other PIs
Awardee OrganizationOREGON HEALTH & SCIENCE UNIVERSITY
Description
Abstract Text
ABSTRACT
Growing evidence indicates that the biological response to chronic social stress and distress can promote the
progression of ovarian precursor lesions and invasive cancer development via prolonged activation of the
sympathetic nervous system and sustained norepinephrine release. While chronic social stress/distress is known
to cause chronic inflammation, key questions remain about how stress-related signaling pathways alter the tumor
immune response, particularly infiltration by immunosuppressive cell types triggered in response to chronic
inflammation, and potential means of mitigating the impact of chronic social stress/distress on immune function.
Specifically, we propose to evaluate the hypothesis that chronic social stress/distress enhances the early and
late progression of ovarian tumors by promoting recruitment and activity of immunosuppressive M2-type tumor-
associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) and that certain medications,
including aspirin and other NSAIDs, beta-blockers, and statins, can disrupt immune dysregulation triggered by
stress/distress. Aim 1 will use data from four long-term prospective cohorts in diverse populations and a
population-based case-control study that have collected self-reported measures of chronic social stress and
distress (e.g., widowhood, social isolation, depression, anxiety) and ovarian tumor tissue for tissue microarrays.
Aim 1 will measure intratumoral immune markers to assess TAM, including polarization from the M1 to the M2
immunosuppressive phenotype, and MDSC infiltration, using multiplex immunofluorescence. We hypothesize
that chronic social stress and distress are positively related to ovarian tumor immune suppression (e.g.,
increased ratio of M2:M1 TAMs, MDSCs) and that the association of these exposures with ovarian cancer
diagnosis and associated tumor immune suppression (exploratory) is attenuated among users of aspirin, non-
aspirin NSAIDs, beta-blockers, or statins. Using an orthogonal and interactive approach, Aim 2 will use
experimental ovarian cancer mouse models to examine the effects of chronic unpredictable and predictable
stress occurring before and after inoculation on MDSCs, monocyte, and TAM populations as well as cytokine
networks by polychromatic flow cytometry and multiplex assays. We also will examine if aspirin and one other
medication informed by the analyses in humans and existing literature counteracts the effects of chronic stress
on TAM, MDSCs, and monocyte infiltration, polarization, and tumor progression. We hypothesize that pre-
inoculation chronic stress exacerbates post-inoculation chronic stress-induced ovarian cancer progression in
mouse models by up-regulating TAM infiltration, M2 polarization, and MDSC infiltration. In addition, we
hypothesize that aspirin will abrogate these effects. This innovative application will inform future work to identify
women at increased risk for tumoral immune profiles associated with poor prognosis and to develop novel
immunopreventive strategies, pharmacotherapies, and psychosocial interventions to prevent and treat invasive
ovarian cancer in women who experience chronic social stress and distress.
Public Health Relevance Statement
PROJECT NARRATIVE
This application integrates research using human populations and experimental approaches to elucidate how
stress-induced signaling pathways alter ovarian tumor-associated immunity, particularly immunosuppressive
cell types, and to assess anti-inflammatory medications that may mitigate these effects. Our synergistic
approach will shed light on mechanisms by which chronic stress and distress enhance early and late disease
progression, and provide new targets for cancer interception.
No Sub Projects information available for 7R01CA276224-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01CA276224-02
Patents
No Patents information available for 7R01CA276224-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01CA276224-02
Clinical Studies
No Clinical Studies information available for 7R01CA276224-02
News and More
Related News Releases
No news release information available for 7R01CA276224-02
History
No Historical information available for 7R01CA276224-02
Similar Projects
No Similar Projects information available for 7R01CA276224-02